Simple jQuery Dropdowns
Please use this identifier to cite or link to this item:
Title: Model-Informed Drug Development for Malaria Therapeutics
Authors: Kayla Ann Andrews
David Wesche
James McCarthy
Jörg J. Möhrle
Joel Tarning
Luann Phillips
Steven Kern
Thaddeus Grasela
University at Buffalo, State University of New York
University of Queensland
QIMR Berghofer Medical Research Institute
Bill and Melinda Gates Foundation
Mahidol University
Nuffield Department of Clinical Medicine
Cognigen Corporation
Medicines for Malaria Venture
Keywords: Pharmacology, Toxicology and Pharmaceutics
Issue Date: 6-Jan-2018
Citation: Annual Review of Pharmacology and Toxicology. Vol.58, (2018), 567-582
Abstract: © 2018 Kayla Ann Andrews et al. Malaria is a critical public health problem resulting in substantial morbidity and mortality, particularly in developing countries. Owing to the development of resistance toward current therapies, novel approaches to accelerate the development efforts of new malaria therapeutics are urgently needed. There have been significant advancements in the development of in vitro and in vivo experiments that generate data used to inform decisions about the potential merit of new compounds. A comprehensive disease-drug model capable of integrating discrete data from different preclinical and clinical components would be a valuable tool across all stages of drug development. This could have an enormous impact on the otherwise slow and resource-intensive process of traditional clinical drug development.
ISSN: 15454304
Appears in Collections:Scopus 2018

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.